921 related articles for article (PubMed ID: 26239094)
1. Antithrombotic Treatment Patterns in Patients with Newly Diagnosed Nonvalvular Atrial Fibrillation: The GLORIA-AF Registry, Phase II.
Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma C; Zint K; Elsaesser A; Bartels DB; Lip GY;
Am J Med; 2015 Dec; 128(12):1306-13.e1. PubMed ID: 26239094
[TBL] [Abstract][Full Text] [Related]
2. Antithrombotic therapy use in patients with atrial fibrillation before the era of non-vitamin K antagonist oral anticoagulants: the Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) Phase I cohort.
Huisman MV; Ma CS; Diener HC; Dubner SJ; Halperin JL; Rothman KJ; Teutsch C; Schoof N; Kleine E; Bartels DB; Lip GY;
Europace; 2016 Sep; 18(9):1308-18. PubMed ID: 27335063
[TBL] [Abstract][Full Text] [Related]
3. The Changing Landscape for Stroke Prevention in AF: Findings From the GLORIA-AF Registry Phase 2.
Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma CS; Zint K; Elsaesser A; Bartels DB; Lip GY;
J Am Coll Cardiol; 2017 Feb; 69(7):777-785. PubMed ID: 28209218
[TBL] [Abstract][Full Text] [Related]
4. Design and rationale of Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation: a global registry program on long-term oral antithrombotic treatment in patients with atrial fibrillation.
Huisman MV; Lip GY; Diener HC; Dubner SJ; Halperin JL; Ma CS; Rothman KJ; Teutsch C; Zint K; Ackermann D; Clemens A; Bartels DB
Am Heart J; 2014 Mar; 167(3):329-34. PubMed ID: 24576516
[TBL] [Abstract][Full Text] [Related]
5. Evolution of antithrombotic therapy for patients with atrial fibrillation: The prospective global GLORIA-AF registry program.
Beier L; Lu S; França LR; Marler S; Lip GYH; Huisman MV; Teutsch C; Halperin JL; Zint K; Diener HC; Baker L; Ma CS; Paquette M; Bartels DB; Dubner SJ; Lyrer P; Senges J; Rothman KJ
PLoS One; 2022; 17(10):e0274237. PubMed ID: 36201473
[TBL] [Abstract][Full Text] [Related]
6. Vitamin K and non-vitamin K antagonist oral anticoagulants for non-valvular atrial fibrillation in real-life.
Giustozzi M; Vedovati MC; Verdecchia P; Pierpaoli L; Verso M; Conti S; Cianella F; Marchesini E; Filippucci E; Agnelli G; Becattini C
Eur J Intern Med; 2016 Sep; 33():42-6. PubMed ID: 27394924
[TBL] [Abstract][Full Text] [Related]
7. Stroke-prevention strategies in North American patients with atrial fibrillation: The GLORIA-AF registry program.
McIntyre WF; Conen D; Olshansky B; Halperin JL; Hayek E; Huisman MV; Lip GYH; Lu S; Healey JS
Clin Cardiol; 2018 Jun; 41(6):744-751. PubMed ID: 29546729
[TBL] [Abstract][Full Text] [Related]
8. Regional Differences in Antithrombotic Treatment for Atrial Fibrillation: Insights from the GLORIA-AF Phase II Registry.
Mazurek M; Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma CS; Zint K; Elsaesser A; Lu S; Lip GYH;
Thromb Haemost; 2017 Dec; 117(12):2376-2388. PubMed ID: 29212125
[TBL] [Abstract][Full Text] [Related]
9. Oral anticoagulant therapy for stroke prevention in patients with atrial fibrillation undergoing ablation: results from the First European Snapshot Survey on Procedural Routines for Atrial Fibrillation Ablation (ESS-PRAFA).
Potpara TS; Larsen TB; Deharo JC; Rossvoll O; Dagres N; Todd D; Pison L; Proclemer A; Purefellner H; Blomström-Lundqvist C;
Europace; 2015 Jun; 17(6):986-93. PubMed ID: 26023177
[TBL] [Abstract][Full Text] [Related]
10. Evolving antithrombotic treatment patterns for patients with newly diagnosed atrial fibrillation.
Camm AJ; Accetta G; Ambrosio G; Atar D; Bassand JP; Berge E; Cools F; Fitzmaurice DA; Goldhaber SZ; Goto S; Haas S; Kayani G; Koretsune Y; Mantovani LG; Misselwitz F; Oh S; Turpie AG; Verheugt FW; Kakkar AK;
Heart; 2017 Feb; 103(4):307-314. PubMed ID: 27647168
[TBL] [Abstract][Full Text] [Related]
11. Real world time trends in antithrombotic treatment for newly diagnosed atrial fibrillation in China: reports from the GLORIA-AF Phase III registry : Trends in antithrombotic therapy use in China.
Liu X; Feng G; Marler SV; Huisman MV; Lip GYH; Ma C
Thromb J; 2023 Aug; 21(1):83. PubMed ID: 37528405
[TBL] [Abstract][Full Text] [Related]
12. Dabigatran versus vitamin K antagonists for atrial fibrillation in clinical practice: final outcomes from Phase III of the GLORIA-AF registry.
Huisman MV; Teutsch C; Lu S; Diener HC; Dubner SJ; Halperin JL; Ma CS; Rothman KJ; Lohmann R; Gurusamy VK; Bartels DB; Lip GYH;
Clin Res Cardiol; 2022 May; 111(5):548-559. PubMed ID: 35294623
[TBL] [Abstract][Full Text] [Related]
13. A prospective survey in European Society of Cardiology member countries of atrial fibrillation management: baseline results of EURObservational Research Programme Atrial Fibrillation (EORP-AF) Pilot General Registry.
Lip GY; Laroche C; Dan GA; Santini M; Kalarus Z; Rasmussen LH; Oliveira MM; Mairesse G; Crijns HJ; Simantirakis E; Atar D; Kirchhof P; Vardas P; Tavazzi L; Maggioni AP
Europace; 2014 Mar; 16(3):308-19. PubMed ID: 24351881
[TBL] [Abstract][Full Text] [Related]
14. Antithrombotic treatment for newly diagnosed atrial fibrillation in relation to patient age: the GLORIA-AF registry programme.
Mazurek M; Halperin JL; Huisman MV; Diener HC; Dubner SJ; Ma CS; Rothman KJ; Healey JS; Teutsch C; Paquette M; França LR; Lu S; Bartels DB; Lip GYH
Europace; 2020 Jan; 22(1):47-57. PubMed ID: 31651951
[TBL] [Abstract][Full Text] [Related]
15. 'Real-world' antithrombotic treatment in atrial fibrillation: The EORP-AF pilot survey.
Lip GY; Laroche C; Dan GA; Santini M; Kalarus Z; Rasmussen LH; Ioachim PM; Tica O; Boriani G; Cimaglia P; Diemberger I; Hellum CF; Mortensen B; Maggioni AP
Am J Med; 2014 Jun; 127(6):519-29.e1. PubMed ID: 24486284
[TBL] [Abstract][Full Text] [Related]
16. Antithrombotic Usage, Including Three-Year Outcomes With Dabigatran and Vitamin K Antagonists for Atrial Fibrillation, in Eastern Europe: A Descriptive Analysis From Phase 3 of the GLORIA-AF Registry.
Bergler-Klein J; Gotcheva N; Kalējs O; Kalarus Z; Kovačić D; Peršić V; Shlyakhto E; Uuetoa T; Huisman MV; Lip GYH; Vinereanu D;
Am J Ther; 2024 Jan-Feb 01; 31(1):e1-e12. PubMed ID: 38231576
[TBL] [Abstract][Full Text] [Related]
17. Stroke prevention in atrial fibrillation patients in Poland and other European countries: insights from the GARFIELD-AF registry.
Stępińska J; Kremis E; Konopka A; Wożakowska-Kapłon B; Ruszkowski P; Kukla P; Kayani G
Kardiol Pol; 2016; 74(4):362-71. PubMed ID: 26365937
[TBL] [Abstract][Full Text] [Related]
18. Comparison of clinical characteristics of real-life atrial fibrillation patients treated with vitamin K antagonists, dabigatran, and rivaroxaban: results from the CRAFT study.
Balsam P; Ozierański K; Tymińska A; Żukowska K; Zaleska M; Szepietowska K; Maciejewski K; Peller M; Grabowski M; Lodziński P; Praska-Ogińska A; Zaboyska I; Kołtowski Ł; Kowalczuk A; Bednarski J; Filipiak KJ; Opolski G
Kardiol Pol; 2018; 76(5):889-898. PubMed ID: 29350386
[TBL] [Abstract][Full Text] [Related]
19. Use of non-vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic.
Lee SI; Sayers M; Lip GY; Lane DA
Int J Clin Pract; 2015 Nov; 69(11):1341-8. PubMed ID: 26234557
[TBL] [Abstract][Full Text] [Related]
20. Two-year follow-up of patients treated with dabigatran for stroke prevention in atrial fibrillation: Global Registry on Long-Term Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) registry.
Huisman MV; Rothman KJ; Paquette M; Teutsch C; Diener HC; Dubner SJ; Halperin JL; Ma CS; Zint K; Elsaesser A; Lu S; Bartels DB; Lip GYH;
Am Heart J; 2018 Apr; 198():55-63. PubMed ID: 29653649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
